SERNOVA Forum: Community User: COLOGNE79

Damit die Leute das hier auch verstehen, 5 CAD = 3,75 Euro jetzt und nicht erst 2026/2029 oder 2030!! Endchance 50:50!! A phase III trial in 30 patients may take up to three years with ample follow up. A subsequent launch would occur in 2026. Conformal coated iPSCs places in a Cell Pouch might begin commercialization in 2029. The probability of success of the latter is assumed to be 50%. During the initial phase of commercialization, given limited supply of cadaveric islet cells, we anticipate a rather shallow market penetration with less than 300 patients treated in total, which is expected to generate $50-$100 million. We expect market penetration/adoption to increase substantially with the arrival of iPSC-derived ß-cells. Rememebr this is a brand new therapeutic modality. Therefore, market adoption, payer coverage, etc. are highly speculative. For the second phase of commercialization, we anticipate a prolonged ramp of increases in annual sales, leading to a peak sales figure of approximately $6.5 billion and peak patient adoption of approximately 18,000 patients per year by 2035-36. Our estimates for the Cell Pouch that contains iPSC-derived ß-cells include opportunity in the pediatric diabetic population, who are newly diagnosed with T1D at an early age. See our model for additional details.

alternativ https://cdn-ceo-ca.s3.amazonaws.com/1hijgfq-ROTH+Capital+Partners+-+Sernova+Coverage+Report+-+%245+CDN+Price+Target.pdf

Damit die Leute das hier auch verstehen, 5 CAD = 3,75 Euro jetzt und nicht erst 2026/2029 oder 2030!! Endchance 50:50!! A phase III trial in 30 patients may take up to three years with ample follow up. A subsequent launch would occur in 2026. Conformal coated iPSCs places in a Cell Pouch might begin commercialization in 2029. The probability of success of the latter is assumed to be 50%. During the initial phase of commercialization, given limited supply of cadaveric islet cells, we anticipate a rather shallow market penetration with less than 300 patients treated in total, which is expected to generate $50-$100 million. We expect market penetration/adoption to increase substantially with the arrival of iPSC-derived ß-cells. Rememebr this is a brand new therapeutic modality. Therefore, market adoption, payer coverage, etc. are highly speculative. For the second phase of commercialization, we anticipate a prolonged ramp of increases in annual sales, leading to a peak sales figure of approximately $6.5 billion and peak patient adoption of approximately 18,000 patients per year by 2035-36. Our estimates for the Cell Pouch that contains iPSC-derived ß-cells include opportunity in the pediatric diabetic population, who are newly diagnosed with T1D at an early age. See our model for additional details.